• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
    • Oncology
    • Neurology
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Patients with Breast Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
    • Oncology
    • Neurology
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Patients with Breast Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
04JunJune 4, 2024

ASCO 2024

31MayMay 31, 2024

ARV-766, A PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer: Initial Results of a Phase 1/2 Study

06MayMay 6, 2024

AUA 2024

03MayMay 3, 2024

ARV-766, a PROTAC Androgen Receptor Degrader, Combined With Abiraterone in Novel Hormonal Agent–Naïve Metastatic Prostate Cancer: Phase 1 Cohort (Part C) of a Phase 1/2 Study

13SepSeptember 13, 2023

ISSX 2023

12SepSeptember 12, 2023

ACCP 2023

10SepSeptember 10, 2023

In Vitro Evaluation of PROTAC® Androgen Receptor Degrader ARV-766 for Cytochrome P450- and Transporter-Mediated Drug-Drug Interaction

10SepSeptember 10, 2023

The Effect of Food and the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of ARV-766, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Healthy Volunteers

14AprApril 14, 2023

AACR 2023

14AprApril 14, 2023

Discovery of ARV-766, an Androgen Receptor Degrading PROTAC® for the Treatment of Men with Metastatic Castration Resistant Prostate Cancer

12Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE